Article ID Journal Published Year Pages File Type
5705540 Ophthalmology 2016 8 Pages PDF
Abstract
Treatment of noninfectious uveitis with adalimumab is associated with high rates of favorable clinical response. Overall, adalimumab trough levels were higher in responder patients. Development of permanent AAA was associated with undetectable trough adalimumab levels and worse uveitis outcome. Immunogenicity was more common in patients in whom uveitis was associated with a systemic disease and was not influenced by concomitant immunosuppressors.
Related Topics
Health Sciences Medicine and Dentistry Ophthalmology
Authors
, , , , , , , , ,